Clinical Design and Research Objectives

The NCT00001406 study, sponsored by the National Institute of Allergy and Infectious Diseases (NIAID), is a non-interventional, observational natural history study designed to characterize the clinical and genetic heterogeneity of eosinophilic diseases, rather than a drug administration clinical trial. It began in April 1997, is currently recruiting with a renewal date of July 2026, and aims to enroll approximately 800 patients. The study involves long-term follow-up of patients aged 1 to 100 years with peripheral blood eosinophil counts exceeding 750 per microliter or abnormal tissue accumulation, along with some family members, to correlate disease etiology, organ damage, and treatment response.

Biomarkers and Patient Stratification

Repeated collection of blood, bone marrow, tissue, and body fluids, with adults potentially undergoing leukapheresis, allows for the analysis of both tissue infiltration and cellular activation, which may not be captured by blood levels alone. The primary outcome measure is the identification of clinical and genetic variants of hypereosinophilic syndrome (HES), and the study also evaluates biomarkers of disease activity and organ involvement, diagnostic algorithms, and novel therapeutic targets. This aims to reduce misdiagnosis and variability in treatment response that can occur when different etiologies of PDGFRA-associated myeloproliferative diseases, lymphocytic HES, and idiopathic HES are grouped together based solely on eosinophil counts.

Competitive Landscape and Regulatory History

The current leading targeted therapy for HES is Nucala (mepolizumab) from GSK, which blocks interleukin-5 (IL-5) and promotes eosinophil survival. It was approved by the FDA on September 25, 2020, for the treatment of HES. For FIP1L1-PDGFRA-positive myeloproliferative diseases, Gleevec (imatinib), which inhibits the PDGFRA tyrosine kinase, is a key treatment. Other treatments include systemic glucocorticoids and immunosuppressants. Fasenra (benralizumab) from AstraZeneca (AZN) targets the IL-5 receptor alpha to deplete eosinophils and has accumulated Phase 2 data in PDGFRA-negative HES, but Nucala is the only FDA-approved HES treatment in the United States. Fasenra was approved by the FDA in September 2024 for adult eosinophilic granulomatosis with polyangiitis (EGPA), securing a competitive advantage in an adjacent indication.

Commercial Significance and Research Productivity

The commercial potential of eosinophil-based diseases as a whole is greater than that of rare HES alone. Nucala generated respiratory and eosinophilic disease sales of £2 billion in 2025, and Fasenra generated global product sales of $1.981 billion in the same year. Therefore, the tissue biomarkers and molecular subtypes identified by this cohort can be directly applied to screen patients who are likely to respond to existing IL-5-targeted therapies, reduce steroid use, and design clinical trials for new targets. This natural history cohort has provided patient and long-term follow-up data for benralizumab's Phase 2 study in PDGFRA-negative HES and for the analysis of responses to mepolizumab and imatinib.

Why It Matters

A large-scale, long-term natural history study provides the data infrastructure needed for clinical trial recruitment, patient stratification, and long-term safety assessment in rare HES. From an investment perspective, biomarkers that predict response in the IL-5 market, which generated £2 billion in sales for Nucala and $1.981 billion for Fasenra in 2025, will determine market share and indication expansion. For researchers, the linked blood, bone marrow, and tissue samples, along with genetic subtype data such as PDGFRA, serve as a benchmark for validating new targets and designing Phase 2 studies. In the industry, the short-term competitive focus is on precision diagnostics that differentiate between FDA-approved HES treatments such as Nucala, Fasenra with Phase 2 HES data, and Gleevec for PDGFRA-positive patients, while the medium- to long-term focus is on developing new drugs that directly measure tissue eosinophil activity and organ damage.